Evidence map›Paper›PMID 31938949›Full record

ArticleInvestigational new drugs2020

Efficacy of different dosing schedules of capecitabine for metastatic breast cancer: a single-institution experience.

Anupama Suresh, Akannsha Ganju, Evan Morgan, Marilly Palettas, Julie A Stephens, Joseph Liu, Michael Berger, Craig Vargo, Anne Noonan, Raquel Reinbolt and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Observational
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Anupama SureshStefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Akannsha GanjuStefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Evan MorganStefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Marilly PalettasDepartment of Biomedical Informatics, Center for Biostatistics, The Ohio State University, Columbus, OH, USA.
Julie A StephensDepartment of Biomedical Informatics, Center for Biostatistics, The Ohio State University, Columbus, OH, USA.
Joseph LiuStefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Michael BergerStefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Craig VargoStefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Anne NoonanStefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Raquel ReinboltStefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Mathew CherianStefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Jeffrey VanDeusenStefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Sagar SardesaiStefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Robert WesolowskiStefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Daniel G StoverStefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Maryam LustbergStefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Bhuvaneswari RamaswamyStefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Nicole WilliamsStefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA. Nicole.Williams@osumc.edu.ORCID http://orcid.org/0000-0002-0339-1612

Funding

The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve HealthUL1TR002733 · NCATS · OHIO STATE UNIVERSITY · PI RINGEL, MATTHEW D · 2018 to 2022
$28.9M
Cancer Clinical Investigator Team Leadership Award P30CA016058-42S2NCATS NIH HHS UL1TR002733
6 · The paper itself

Abstract

Purpose Capecitabine is widely used as a single agent on a 21-day cycle in the management of metastatic breast cancer (MBC). Our primary objective was to compare the standard dosing of capecitabine (Arm A: days 1-14 on 21-day cycle) to biweekly dosing (Arm B: days 1-7 and 15-21 on 28-day cycle) using retrospective data analysis. Methods 166 patients with MBC treated with single agent capecitabine at The Ohio State University from 2002 to 2014 were considered eligible. Median time to treatment failure (TTF) and overall survival (OS) were estimated using Kaplan-Meier (KM) methods. KM curves were compared using log-rank tests with Holm's correction for multiplicity. Results Patients were grouped by dose schedule into one of three arms: Arm A (21-day cycle; capecitabine given at 1000 mg/m

Indexed as

AdultAgedAntimetabolites, AntineoplasticBreast NeoplasmsCapecitabineDrug Administration ScheduleFemaleHumansKaplan-Meier EstimateMiddle AgedRetrospective StudiesTreatment FailureAntimetabolites, AntineoplasticCapecitabineCapecitabineDosing schedulesMetastatic breast cancerSurvival analysis

Identifiers

PMID31938949

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.